Cystic fibrosis

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

New DDW Highlights podcast: 22 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week all concerns clinical trials for new drugs that could… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

This week in drug discovery (15-19 April) 

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More

#News

#Cystic fibrosis #Ireland #Paediatrics #Respiratory #Vertex

Landmark study supports use of cystic fibrosis drug in newborns

A cystic fibrosis drug targeting the basic defect that causes the condition has been shown to be safe and effective in newborns aged four weeks and above, new research has found. The study, involving RCSI University of Medicine and Health Sciences and Children’s Health Ireland, included… Read More

#News

Mother helps child to use a nebuliser
#Cystic fibrosis #European Commission #Gene mutation #Genetics / genomics #Paediatrics #Vertex

EU extends paediatric use of combination in cystic fibrosis

A label expansion for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) has been approved in the European Union (EU). The European Commission has extended use of the therapy to include children with CF aged two through five years old who have at… Read More

#News #Regulatory

Double stranded DNA molecule with mutation in a gene
#Cystic fibrosis #Life sciences #Seed funding #Start-ups #Therapeutics

€2m raised in seed funding to develop novel therapies for Cystic Fibrosis  

Anoat Therapeutics, a preclinical stage biotechnology company specialised in Cystic Fibrosis (CF), has raised €2m ($2.17m) in seed funding from AdBio partners, a venture capital company specialised in seed investments in life sciences startups.   This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership… Read More

#News #Start-up Zone

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News

Child with cystic fibrosis on ventilator
#Cell and gene therapy #Cystic fibrosis #European Commission #Gene therapy #Krystal Biotech #Orphan drugs

Gene therapy for cystic fibrosis receives EC orphan drug designation

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered… Read More

#News #Regulatory

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer. Amid continued… Read More

#News

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer and reflects… Read More

#News

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News

Child with cystic fibrosis on ventilator
#Antimicrobial resistance (AMR) #Cystic fibrosis #Drug discovery

Partnership seeks to transform Cystic Fibrosis research

LifeArc, a national medical research charity, is joining the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate in a strategic partnership alongside Cystic Fibrosis Trust and Medicines Discovery Catapult (MDC). The CF AMR Syndicate aims to address unmet patient needs by linking people with CF with leading experts across industry, academia… Read More

#News

#Antimicrobial resistance (AMR) #Cystic fibrosis

Destiny Pharma granted award from Cystic Fibrosis Foundation  

Biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation to help the company advance its lead compound for cystic fibrosis patients who have been infected with methicillin-resistant Staphylococcus aureus (MRSA).  Destiny Pharma will establish a research project with the Cystic Fibrosis Foundation where… Read More

#News